![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
Our Specialty Pharmacy Enablement (SPE) expert discusses 3 critical areas of access for the health system specialty pharmacy.
MHS In the News: Andrew Wilson Answers "One Burning Question"
A 340B expert discusses how to make sure the program is benefiting patients.
By
Date
August 17, 2021
Listen time: 7 minutes
A key goal of the 340B Drug Pricing Program is to allocate additional revenue to health services for patients in underserved communities, such as free care for uninsured patients, free vaccines, mental health treatment and more. While overall 340B savings is tracked and managed by hospitals, oftentimes it is not delivered back to the hospitals to invest in such programs. Instead, it can be consumed by high billing and operating costs.
In a conversation with Keith Streckenbach of Pharmacy Practice News, Andrew Wilson, vice president, 340B Solutions for McKesson, discusses this one burning question pertaining to 340B: “Have you examined how your actions with the 340B Drug Pricing Program are benefitting your patients?”
Listen to hear what he shared.
Related Stories
One of our McKesson experts discusses the importance of staying informed as 340B changes continue to unfold.
The most downloaded content by health system pharmacy leaders in August 2025.
As payer dynamics shift, therapy pipelines grow, and leakage accelerates, health systems leaders should rethink what infusion care can and should be.
Expert insights into prioritizing 340B as a system-wide program in your health system.
The most downloaded content by health system pharmacy leaders in July 2025.
A recent podcast includes first-hand insights on opportunities for collaboration in strengthening the supply chain to achieve more.
McKesson’s Head of Cell, Gene, and Advanced Therapies discusses opportunities and challenges with CGT in the health system.
This interactive experience highlights key aspects of our SPE solutions, designed to help your health system achieve more.
The first in a series of interviews with our Specialty Pharmacy Enablement expert, Ginger Thorpe, covering important questions health systems should be asking.